Becton Dickinson & Co. 's announcement in January that it is entering the diabetes testing business laid to rest questions about its commitment to a field it has tinkered with for years. The move, however, raised new speculation about the company's ability to make inroads in a market it is entering late and which is dominated by Roche and Johnson & Johnson , who are willing to protect their lucrative shares of the monitoring business with heavy product development and marketing spending.
Prepared for the skepticism, BD executives simultaneously announced separate strategic relationships with two health care gorillas, Medtronic Inc. [See...